We in-licensed ferric citrate in 2006. Since that time, we conducted Phase 2 and pivotal Phase 3 clinical trials, received approval by the U.S. Food and Drug Administration (FDA) under the brand Auryxia® (ferric citrate), procured a sub-licensing arrangement/partnership in Japan, and received European approval for Fexeric®, the brand name in Europe.
We are partnered with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd., for the development and commercialization of ferric citrate in Japan. Marketing approval was granted in Japan in early 2014, and the medicine, known as Riona®, was launched by Torii in May, 2014. Keryx receives royalties on net sales in Japan. Keryx holds a worldwide license (except for certain Asian Pacific countries) to ferric citrate.
Our business development activities are focused on complementing our internal development and commercial capabilities with external therapies that may help us bring innovative medicines to the kidney community. We may engage in business development activities that include seeking strategic relationships for Auryxia, as well as evaluating other therapies and companies for in-licensing or acquisition.
If you are interested in discussing potential partnerships with us, please contact us at email@example.com.
We plan to opportunistically identify additional drug candidates for in-licensing or acquisition that could leverage both our clinical development expertise and, ultimately, the commercial infrastructure we are building to serve the kidney community.